In addition to infiltrating immune cells, Bregs also directly interacted with liver cancer cells through the CD40/CD154 signaling pathway to enhance HCC growth and invasion (48), indicating that disruption of tumor-Breg interactions might be a potential therapeutic strategy to treat HCC. The gene discussed is CD40; the disease is hepatocellular carcinoma.